Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
Interleukin-17 (IL-17), a potent pro-inflammatory cytokine, plays an active role in inflammation and cancer. Recently, we found that increased IL-17-producing cells correlate with poor survival and increased lymphangiogenesis in non-small-cell lung cancer (NSCLC), but the mechanism is unknown. Here, we show that IL-17 promotes lymphangiogenesis via inducing vascular endothelial growth factor-C (VEGF-C) production by lung cancer cells. We found that IL-17 receptor (IL-17R) is expressed on the surface of Lewis lung carcinoma (LLC) cells but not on lymphatic endothelial cells (LEC). Moreover, LEC chemotaxis and tube formation (measures of net lymphangiogenic potential) were increased by conditioned medium from recombinant mouse IL-17 (rmIL-17)-stimulated LLC but not by rmIL-17. Interleukin-17 increased production of VEGF-C in lung cancer cell lines. The enhanced chemotaxis and endothelial cord formation in the presence of LLC/rmIL-17 was inhibited by addition of recombinant mouse VEGF R3/Fc chimera. Treatment of the A549 cells with rIL-17 significantly increased VEGF-C expression, which was extracellular signal-regulated protein kinase 1/2 (ERK 1/2) dependent. Importantly, we found significant correlations between IL-17 expression, VEGF-C expression and lymphatic vascular density (LVD) in NSCLC. We conclude that IL-17 is involved in lymphangiogenesis in NSCLC by enhancing production of VEGF-C, and IL-17 may be an important target for the treatment of NSCLC.
Chen
Xi
X
Institute of Cancer Institute of Respiratory Diseases Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Xie
Qichao
Q
Cheng
Xiaoming
X
Diao
Xinwei
X
Cheng
Yue
Y
Liu
Jiankun
J
Xie
Wei
W
Chen
Zhengtang
Z
Zhu
Bo
B
D000818:Animals; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002633:Chemotaxis / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D020381:Interleukin-17 / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D042583:Lymphangiogenesis; D051379:Mice; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D053722:Receptors, Interleukin-17 / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism
D017077:Culture Media, Conditioned; D020381:Interleukin-17; D053722:Receptors, Interleukin-17; D011994:Recombinant Proteins; D042582:Vascular Endothelial Growth Factor C; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
Biochem Biophys Res Commun. 2008 Dec 19;377(3):826-31
18951870
Pharmacology. 2008;82(2):148-55
18667841
Nat Immunol. 2005 Nov;6(11):1133-41
16200068
J Hepatol. 2009 May;50(5):980-9
19329213
Semin Diagn Pathol. 1993 Nov;10(4):302-13
7511250
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10
18832156
Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8
11401524
Immunity. 1995 Dec;3(6):811-21
8777726
J Immunol. 2005 Nov 1;175(9):6177-89
16237115
Pharmacology. 2007;80(4):207-18
17622766
Cell. 2000 Jan 7;100(1):57-70
10647931
Osteoarthritis Cartilage. 2006 Apr;14(4):345-52
16311048
Blood. 2007 Feb 1;109(3):1010-7
17032920
Blood. 2003 Apr 1;101(7):2620-7
12411307
Osteoarthritis Cartilage. 2004 Sep;12(9):683-91
15325633
Lung Cancer. 2010 Sep;69(3):348-54
20022135
Biochem Biophys Res Commun. 2006 Sep 8;347(4):852-8
16859642
Lung Cancer. 2007 Nov;58(2):205-13
17686546
J Immunol. 2009 Oct 1;183(7):4169-75
19767566
Development. 1996 Dec;122(12):3829-37
9012504
Semin Surg Oncol. 2003;21(2):128-37
14508863
Immunity. 2004 Oct;21(4):467-76
15485625
Infect Immun. 2004 Sep;72(9):5019-26
15321994
Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L268-73
16003000
J Biol Chem. 1998 Apr 3;273(14):8413-8
9525952
Clin Cancer Res. 2005 Oct 15;11(20):7344-53
16243806